A clinical analysis of micafungin treatment of pulmonary invasive fungal infection in pediatric patients with acute leukemia or post hematopoietic stem cells transplantation

Objective: To investigate the efficacy and safety of micafungin (MCF) for pulmonary invasive fungal disease (PIFD) in pediatric patients with acute leukemia or post hematopoietic stem cells transplantation. Method: Twenty-five neutropenic PIFD children with acute leukemia or post hematopoietic stem...

Ausführliche Beschreibung

Bibliographische Detailangaben
Veröffentlicht in:Zhonghua er ke za zhi = Chinese journal of pediatrics. - 1960. - 55(2017), 11 vom: 02. Nov., Seite 844-847
1. Verfasser: Huang, K (VerfasserIn)
Weitere Verfasser: Qiu, K Y, Deng, L L, Fang, J P, Li, Y, Guo, H X, Zhou, D H
Format: Online-Aufsatz
Sprache:Chinese
Veröffentlicht: 2017
Zugriff auf das übergeordnete Werk:Zhonghua er ke za zhi = Chinese journal of pediatrics
Schlagworte:Journal Article Child Hematopoietic stem cell transplantation Leukemia Mycoses Echinocandins Lipopeptides Micafungin R10H71BSWG
LEADER 01000naa a22002652 4500
001 NLM278077668
003 DE-627
005 20231225015730.0
007 cr uuu---uuuuu
008 231225s2017 xx |||||o 00| ||chi c
024 7 |a 10.3760/cma.j.issn.0578-1310.2017.11.011  |2 doi 
028 5 2 |a pubmed24n0926.xml 
035 |a (DE-627)NLM278077668 
035 |a (NLM)29141316 
040 |a DE-627  |b ger  |c DE-627  |e rakwb 
041 |a chi 
100 1 |a Huang, K  |e verfasserin  |4 aut 
245 1 2 |a A clinical analysis of micafungin treatment of pulmonary invasive fungal infection in pediatric patients with acute leukemia or post hematopoietic stem cells transplantation 
264 1 |c 2017 
336 |a Text  |b txt  |2 rdacontent 
337 |a ƒaComputermedien  |b c  |2 rdamedia 
338 |a ƒa Online-Ressource  |b cr  |2 rdacarrier 
500 |a Date Completed 23.03.2018 
500 |a Date Revised 02.12.2018 
500 |a published: Print 
500 |a Citation Status MEDLINE 
520 |a Objective: To investigate the efficacy and safety of micafungin (MCF) for pulmonary invasive fungal disease (PIFD) in pediatric patients with acute leukemia or post hematopoietic stem cells transplantation. Method: Twenty-five neutropenic PIFD children with acute leukemia or post hematopoietic stem cells transplantation in Sun Yat-sen Memorial Hospital of Sun Yat-sen University were selected from January 2012 to June 2015, including 12 males and 13 females, age range 2-15 (average 6.2±2.0) years. There were 12 cases of acute leukemia (AL) after chemotherapy, 4 cases of acute leukemia (AL) after allogeneic hematopoietic stem cell transplantation (allo-HSCT) and 9 cases of β-thalassemia major after allo-HSCT. All children received MCM for the treatment of PIFD, the dosage of MCM was 3-4 mg/ (kg·d) , once a day. The children received 2 to 6 courses of treatment, individually with a course of 7 days. 1, 3-β-D glucan assay (G test), galactomannan antigen test (GM test), high-resolution CT and the biochemical indexes for organ functions were closely monitored. Result: Twenty-five cases were diagnosed as PIFD, including 2 patients diagnosed as proven, 6 as probable and 17 as possible. Of the 25 cases, 1 was confirmed aspergillus by biopsy pathology and 1 was candida albicans by blood culture. The G and GM test with positive results was 5 and 2 respectively. Chest CT scans of the 25 cases had obvious lesions: air crescent sign and cavitation in 4 cases, diffuse ground glass change in 9 cases, double lung scattered patchy, small nodules and cord like high density shadow in 7 cases, unilateral or bilateral chest wall wedge-shaped consolidation edge in 5 cases and pleural effusion in 5 patients. The effective rate of MCF in treatment of PIFD was 68% (17/25), including 13 cases cured, 4 cases improved, 4 cases were improved clinically and in 4 cases the treatment was ineffective. Eight cases were effective in MCF monotherapy group (12 cases) and nine were effective in MCF combined therapy group(13 cases), respectively. Side-effects including allergies, gastrointestinal side effects, electrolyte disturbances, impairment of liver and kidney function, and myelosuppression were not found in those children treated with MCF. Conclusion: Micafungin is effective and safe in the treatment of pulmonary invasive fungal disease in pediatric patients with acute leukemia or post hematopoietic stem cell transplantation 
650 4 |a Journal Article 
650 4 |a Child 
650 4 |a Hematopoietic stem cell transplantation 
650 4 |a Leukemia 
650 4 |a Mycoses 
650 7 |a Echinocandins  |2 NLM 
650 7 |a Lipopeptides  |2 NLM 
650 7 |a Micafungin  |2 NLM 
650 7 |a R10H71BSWG  |2 NLM 
700 1 |a Qiu, K Y  |e verfasserin  |4 aut 
700 1 |a Deng, L L  |e verfasserin  |4 aut 
700 1 |a Fang, J P  |e verfasserin  |4 aut 
700 1 |a Li, Y  |e verfasserin  |4 aut 
700 1 |a Guo, H X  |e verfasserin  |4 aut 
700 1 |a Zhou, D H  |e verfasserin  |4 aut 
773 0 8 |i Enthalten in  |t Zhonghua er ke za zhi = Chinese journal of pediatrics  |d 1960  |g 55(2017), 11 vom: 02. Nov., Seite 844-847  |w (DE-627)NLM136249191  |x 0578-1310  |7 nnns 
773 1 8 |g volume:55  |g year:2017  |g number:11  |g day:02  |g month:11  |g pages:844-847 
856 4 0 |u http://dx.doi.org/10.3760/cma.j.issn.0578-1310.2017.11.011  |3 Volltext 
912 |a GBV_USEFLAG_A 
912 |a SYSFLAG_A 
912 |a GBV_NLM 
912 |a GBV_ILN_11 
912 |a GBV_ILN_20 
912 |a GBV_ILN_22 
912 |a GBV_ILN_24 
912 |a GBV_ILN_31 
912 |a GBV_ILN_39 
912 |a GBV_ILN_40 
912 |a GBV_ILN_50 
912 |a GBV_ILN_61 
912 |a GBV_ILN_65 
912 |a GBV_ILN_69 
912 |a GBV_ILN_70 
912 |a GBV_ILN_72 
912 |a GBV_ILN_120 
912 |a GBV_ILN_130 
912 |a GBV_ILN_227 
912 |a GBV_ILN_244 
912 |a GBV_ILN_285 
912 |a GBV_ILN_294 
912 |a GBV_ILN_350 
912 |a GBV_ILN_665 
912 |a GBV_ILN_813 
951 |a AR 
952 |d 55  |j 2017  |e 11  |b 02  |c 11  |h 844-847